TY - JOUR
T1 - MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous
AU - Josephs, Keith A.
AU - Tosakulwong, Nirubol
AU - Graff-Radford, Jonathan
AU - Weigand, Stephen D.
AU - Buciuc, Marina
AU - Machulda, Mary M.
AU - Jones, David T.
AU - Schwarz, Christopher G.
AU - Senjem, Matthew L.
AU - Ertekin-Taner, Nilufer
AU - Kantarci, Kejal
AU - Boeve, Bradley F.
AU - Knopman, David S.
AU - Jack, Clifford R.
AU - Petersen, Ronald C.
AU - Lowe, Val J.
AU - Whitwell, Jennifer L.
N1 - Funding Information:
NIH R01-AG50603, P50-AG16574, P30 AG062677, R01-AG11378, U01-AG006786, and the Elsie and Marvin Dekelboum Family Foundation and the Oxley Foundation. The work was supported by grants from the National Institutes of Health (R01 AG50603 (JLW), P50-AG016574 (RCP), P30 AG062677 (RCP) and U01- AG006786 (RCP)) and The Elsie and Marvin Dekelboum Family Foundation and the Oxley Foundation. We thank AVID Radiopharmaceuticals, Inc., for their support in supplying the AV-1451 precursor, chemistry production advice and oversight, and FDA regulatory cross-filing permission and documentation needed for this work.
Funding Information:
The work was supported by grants from the National Institutes of Health (R01 AG50603 (JLW), P50‐AG016574 (RCP), P30 AG062677 (RCP) and U01‐ AG006786 (RCP)) and The Elsie and Marvin Dekelboum Family Foundation and the Oxley Foundation. We thank AVID Radiopharmaceuticals, Inc., for their support in supplying the AV‐1451 precursor, chemistry production advice and oversight, and FDA regulatory cross‐filing permission and documentation needed for this work.
Publisher Copyright:
© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Objective: To assess the relationships between MRI volumetry and [18F]flortaucipir PET of typical and atypical clinical phenotypes of Alzheimer’s disease, by genarian (age by decade). Methods: Five-hundred and sixty-four participants including those with typical (n = 86) or atypical (n = 80) Alzheimer’s dementia and normal controls (n = 398) underwent apolipoprotein E genotyping, MRI, flortaucipir, and 11C-PiB; all 166 Alzheimer’s participants were beta-amyloid positive and all controls were beta-amyloid negative. Grey matter volume and flortaucipir standard uptake value ratios were calculated for hippocampus, entorhinal cortex, and neocortex. Ratios of hippocampal-to-neocortical and entorhinal-to-neocortical volume and flortaucipir uptake were also calculated. Linear regression models assessed relationships among regional volume, flortaucipir uptake, and ratios and phenotypes, within three genarians (50–59, 60–69, and 70+). Voxel-level analyses were also performed. Results: For 50–59 greater medial temporal atrophy and flortaucipir uptake was observed in the typical compared with atypical phenotype. The typical phenotype also showed greater frontal neocortex uptake with the voxel-level analysis. For 60–69 and 70+ there was greater hippocampal volume loss in the typical compared with atypical phenotype while only the 60–69, but not the 70+ group, showed a difference in hippocampal flortaucipir uptake. We also observed a pattern for higher neocortical flortaucipir uptake to correlate with younger age decade for both phenotypes. Interpretation: MRI volumetry versus flortaucipir PET relationships differ across Alzheimer’s clinical phenotypes, and also within phenotype across age decades. This suggests that there is potential risk of masked effects by not accounting for genarian in participants with beta-amyloid and tau-positive biomarker defined Alzheimer’s disease.
AB - Objective: To assess the relationships between MRI volumetry and [18F]flortaucipir PET of typical and atypical clinical phenotypes of Alzheimer’s disease, by genarian (age by decade). Methods: Five-hundred and sixty-four participants including those with typical (n = 86) or atypical (n = 80) Alzheimer’s dementia and normal controls (n = 398) underwent apolipoprotein E genotyping, MRI, flortaucipir, and 11C-PiB; all 166 Alzheimer’s participants were beta-amyloid positive and all controls were beta-amyloid negative. Grey matter volume and flortaucipir standard uptake value ratios were calculated for hippocampus, entorhinal cortex, and neocortex. Ratios of hippocampal-to-neocortical and entorhinal-to-neocortical volume and flortaucipir uptake were also calculated. Linear regression models assessed relationships among regional volume, flortaucipir uptake, and ratios and phenotypes, within three genarians (50–59, 60–69, and 70+). Voxel-level analyses were also performed. Results: For 50–59 greater medial temporal atrophy and flortaucipir uptake was observed in the typical compared with atypical phenotype. The typical phenotype also showed greater frontal neocortex uptake with the voxel-level analysis. For 60–69 and 70+ there was greater hippocampal volume loss in the typical compared with atypical phenotype while only the 60–69, but not the 70+ group, showed a difference in hippocampal flortaucipir uptake. We also observed a pattern for higher neocortical flortaucipir uptake to correlate with younger age decade for both phenotypes. Interpretation: MRI volumetry versus flortaucipir PET relationships differ across Alzheimer’s clinical phenotypes, and also within phenotype across age decades. This suggests that there is potential risk of masked effects by not accounting for genarian in participants with beta-amyloid and tau-positive biomarker defined Alzheimer’s disease.
UR - http://www.scopus.com/inward/record.url?scp=85083440880&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083440880&partnerID=8YFLogxK
U2 - 10.1002/acn3.51038
DO - 10.1002/acn3.51038
M3 - Article
C2 - 32293805
AN - SCOPUS:85083440880
SN - 2328-9503
VL - 7
SP - 707
EP - 721
JO - Annals of Clinical and Translational Neurology
JF - Annals of Clinical and Translational Neurology
IS - 5
ER -